ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on addressing degenerative diseases, announced today the submission of a design ...

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced it has submitted a Clinical ...

LifeMap Sciences' discovery platform will be used to evaluate approximately 100 million proprietary gene expression data points relating to human embryonic stem cells generated by BioTime scientists ...

BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, Ph.D.

Adds senior executive with significant experience in sales and marketing of research products ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of ...

BEND, OR / ACCESSWIRE / September 22, 2017 / BioTime, Inc. (NASDAQ: BTX), Sylva International has always been extremely interested in regenerative medicines because they've shown tremendous promise in ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus' primary focus will be to ...

BioTime (BTX) came out with quarterly earnings of $0.30 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.09 per share a year ago. These figures ...

ALAMEDA, Calif.--(BUSINESS WIRE)-- BioTime, Inc. (NYSE Amex: BTIM) today reported financial results for the first quarter ended March 31, 2010 and provided an update on recent corporate developments.

Alameda-based BioTime, which has seen its stock double in the past year, reached an agreement this week to provide important embryonic stem cell lines to California-based researchers for free in hopes ...